Αποτελέσματα Αναζήτησης
The National Comprehensive Cancer Network (NCCN) guidelines for the treatment of breast cancer describe numerous recommended adjuvant chemotherapy regimens, including sequential anthracycline-cyclophosphamide and taxane (AC-T); concurrent anthracycline-cyclophosphamide and taxane (ACT); anthracycline-cyclophosphamide without taxane (AC ...
Adjuvant chemotherapy improves outcomes of operable breast cancer. Since the landmark study of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (1), there has been an ongoing effort to identify better regimens to improve survival and decrease toxicity.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
10 Οκτ 2016 · We examined 3 types of costs: 1) drug-related costs, 2) drug-related costs and growth factor-related costs summed, and 3) total costs. We considered both insurance payments and patient out-of-pocket payments.
Across-center price ratios ranged from 2.2 (pertuzumab, 1 mg; 10th percentile–adjusted median price: $16 vs 90th percentile–adjusted median price: $36) to 15.8 (leuprolide 7.5 mg; 10th percentile–adjusted median price: $247 vs 90th percentile–adjusted median price: $3914).
Meaning Results of this study suggest that, based on the conventional willingness-to-pay threshold, pertuzumab, trastuzumab, and chemotherapy would not be considered cost-effective, even if pertuzumab was free.
AC-T. This chemotherapy combination contains the drugs doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and paclitaxel (taxol). Combinations usually work better than single drugs because different drugs kill cancer cells in different ways. Drugs in the AC-T combination:
